Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1995 Apr 11;92(8):3298–3302. doi: 10.1073/pnas.92.8.3298

Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease.

S H Reich 1, M Melnick 1, J F Davies 2nd 1, K Appelt 1, K K Lewis 1, M A Fuhry 1, M Pino 1, A J Trippe 1, D Nguyen 1, H Dawson 1, et al.
PMCID: PMC42153  PMID: 7724556

Abstract

A class of potent nonpeptidic inhibitors of human immunodeficiency virus protease has been designed by using the three-dimensional structure of the enzyme as a guide. By employing iterative protein cocrystal structure analysis, design, and synthesis the binding affinity of the lead compound was incrementally improved by over four orders of magnitude. An inversion in inhibitor binding mode was observed crystallographically, providing information critical for subsequent design and highlighting the utility of structural feedback in inhibitor optimization. These inhibitors are selective for the viral protease enzyme, possess good antiviral activity, and are orally available in three species.

Full text

PDF
3298

Images in this article

3301Fig. 2
on p.3301

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brünger A. T., Kuriyan J., Karplus M. Crystallographic R factor refinement by molecular dynamics. Science. 1987 Jan 23;235(4787):458–460. doi: 10.1126/science.235.4787.458. [DOI] [PubMed] [Google Scholar]
  2. Gehlhaar D. K., Moerder K. E., Zichi D., Sherman C. J., Ogden R. C., Freer S. T. De novo design of enzyme inhibitors by Monte Carlo ligand generation. J Med Chem. 1995 Feb 3;38(3):466–472. doi: 10.1021/jm00003a010. [DOI] [PubMed] [Google Scholar]
  3. Getman D. P., DeCrescenzo G. A., Heintz R. M., Reed K. L., Talley J. J., Bryant M. L., Clare M., Houseman K. A., Marr J. J., Mueller R. A. Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere. J Med Chem. 1993 Jan 22;36(2):288–291. doi: 10.1021/jm00054a014. [DOI] [PubMed] [Google Scholar]
  4. Greenlee W. J. Renin inhibitors. Med Res Rev. 1990 Apr-Jun;10(2):173–236. doi: 10.1002/med.2610100203. [DOI] [PubMed] [Google Scholar]
  5. Hostomsky Z., Appelt K., Ogden R. C. High-level expression of self-processed HIV-1 protease in Escherichia coli using a synthetic gene. Biochem Biophys Res Commun. 1989 Jun 30;161(3):1056–1063. doi: 10.1016/0006-291x(89)91350-8. [DOI] [PubMed] [Google Scholar]
  6. Kempf D. J., Codacovi L., Wang X. C., Kohlbrenner W. E., Wideburg N. E., Saldivar A., Vasavanonda S., Marsh K. C., Bryant P., Sham H. L. Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J Med Chem. 1993 Feb 5;36(3):320–330. doi: 10.1021/jm00055a003. [DOI] [PubMed] [Google Scholar]
  7. Krohn A., Redshaw S., Ritchie J. C., Graves B. J., Hatada M. H. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J Med Chem. 1991 Nov;34(11):3340–3342. doi: 10.1021/jm00115a028. [DOI] [PubMed] [Google Scholar]
  8. Lam P. Y., Jadhav P. K., Eyermann C. J., Hodge C. N., Ru Y., Bacheler L. T., Meek J. L., Otto M. J., Rayner M. M., Wong Y. N. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science. 1994 Jan 21;263(5145):380–384. doi: 10.1126/science.8278812. [DOI] [PubMed] [Google Scholar]
  9. Morrison J. F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta. 1969;185(2):269–286. doi: 10.1016/0005-2744(69)90420-3. [DOI] [PubMed] [Google Scholar]
  10. Nara P. L., Fischinger P. J. Quantitative infectivity assay for HIV-1 and-2. Nature. 1988 Mar 31;332(6163):469–470. doi: 10.1038/332469a0. [DOI] [PubMed] [Google Scholar]
  11. Richards A. D., Phylip L. H., Farmerie W. G., Scarborough P. E., Alvarez A., Dunn B. M., Hirel P. H., Konvalinka J., Strop P., Pavlickova L. Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J Biol Chem. 1990 May 15;265(14):7733–7736. [PubMed] [Google Scholar]
  12. Roberts N. A., Martin J. A., Kinchington D., Broadhurst A. V., Craig J. C., Duncan I. B., Galpin S. A., Handa B. K., Kay J., Kröhn A. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990 Apr 20;248(4953):358–361. doi: 10.1126/science.2183354. [DOI] [PubMed] [Google Scholar]
  13. Thaisrivongs S., Tomich P. K., Watenpaugh K. D., Chong K. T., Howe W. J., Yang C. P., Strohbach J. W., Turner S. R., McGrath J. P., Bohanon M. J. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem. 1994 Sep 30;37(20):3200–3204. doi: 10.1021/jm00046a002. [DOI] [PubMed] [Google Scholar]
  14. Vacca J. P., Dorsey B. D., Schleif W. A., Levin R. B., McDaniel S. L., Darke P. L., Zugay J., Quintero J. C., Blahy O. M., Roth E. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4096–4100. doi: 10.1073/pnas.91.9.4096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Yarchoan R., Mitsuya H., Broder S. Challenges in the therapy of HIV infection. Trends Pharmacol Sci. 1993 May;14(5):196–202. doi: 10.1016/0165-6147(93)90208-2. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES